Reversal of Lipid-Induced Insulin Resistance
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorYale University
About this trial
The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes.
Hepatic mitochondrial oxidation will be assesses using a 3 hour triple tracer study (D7 glucose, 3-13C lactate and 13C4 beta-hydroxybutyrate).
Eligibility criteria
Qualifiers
Healthy, sedentary, non-smoking and not taking any medications other than birth control pills.
Hematocrit >35%
Subjects will have no systemic or organ disease including diabetes.
Subjects will have no history eating disorders.
Disqualifiers
Any subject, who does not fit the inclusion criteria. Including history of eating disorders, any systemic and organ disease including diabetes.
Hematocrit <35%.
Women of childbearing potential, who are not using contraception (as mentioned above) or who are not abstinent.
Subjects who have a regular exercise regimen will not be enrolled.
Trial design
Treatments tested in this trial
- Caloric Restriction
Treatment groups
250 Participants
are divided into 2 treatment groupsLocations
2Magnetic Resonance Research Center (MRRC)06511, New HavenConnecticut, United States
Yale Center for Clinical Investigation HRU06520, New HavenConnecticut, United States
Sponsors and collaborators
Yale University
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov